
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
Keywords: prostatic neoplasms; castration-resistant; receptors; androgen; prostate-specific antigen; MDV 3100; treatment outcome; ADT; androgen deprivation therapy; AR; androgen receptor; mCRPC; metastatic castration resistant prostate cancer; OS; overall survival;